Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Common Equity: 2010-2025

Historic Common Equity for ProPhase Labs (PRPH) over the last 15 years, with Sep 2025 value amounting to $6.9 million.

  • ProPhase Labs' Common Equity fell 82.00% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 82.00%. This contributed to the annual value of $7.4 million for FY2024, which is 85.11% down from last year.
  • ProPhase Labs' Common Equity amounted to $6.9 million in Q3 2025, which was down 40.01% from $11.4 million recorded in Q2 2025.
  • ProPhase Labs' Common Equity's 5-year high stood at $68.2 million during Q2 2022, with a 5-year trough of $6.9 million in Q3 2025.
  • For the 3-year period, ProPhase Labs' Common Equity averaged around $35.7 million, with its median value being $44.1 million (2024).
  • As far as peak fluctuations go, ProPhase Labs' Common Equity spiked by 455.40% in 2021, and later slumped by 85.11% in 2024.
  • ProPhase Labs' Common Equity (Quarterly) stood at $58.6 million in 2021, then grew by 8.53% to $63.6 million in 2022, then declined by 22.39% to $49.4 million in 2023, then tumbled by 85.11% to $7.4 million in 2024, then plummeted by 82.00% to $6.9 million in 2025.
  • Its Common Equity stands at $6.9 million for Q3 2025, versus $11.4 million for Q2 2025 and $15.1 million for Q1 2025.